Navigating hypotony challenges with XEN gel implantation
1Department of Ophthalmology, Faculty of Medicine, Hashemite University, Zarqa, Jordan.
Expert Review of Medical Devices
|March 8, 2024
Summary
The XEN Gel implant offers effective glaucoma treatment by facilitating aqueous humor flow. Even with low intraocular pressure readings, patients may experience positive outcomes, challenging traditional failure definitions.
Area of Science:
- Ophthalmology
- Glaucoma Management
- Medical Devices
Background:
- The XEN Gel is a hydrophilic tube designed for aqueous shunting, adhering to the Hagen-Poiseuille law.
- It aims to reduce intraocular pressure without causing hypotony.
- Glaucoma management is evolving with advanced shunting devices.
Purpose of the Study:
- To review device variability and challenges associated with hypotony in XEN Gel implantation.
- To explore risk factors and management strategies for hypotony.
- To provide insights into the clinical and statistical perspectives of hypotony in glaucoma treatment.
Main Methods:
- Review of existing literature and comparative studies on XEN Gel implantation.
- Analysis of implantation methodologies (ab interno, ab externo, conjunctival opening).
- Evaluation of hypotony incidence and its correlation with patient outcomes.
Main Results:
- No significant outcome differences were observed between various implantation techniques.
- Numerical hypotony (below 6 mmHg) does not always indicate treatment failure; patients can still fare well.
- Hypotony incidence varies between XEN Gel device models.
Conclusions:
- The XEN Gel represents an advancement in glaucoma management, offering versatility in implantation.
- A nuanced understanding of hypotony is crucial, moving beyond simple pressure thresholds.
- Individualized patient assessment and device selection are key to optimizing XEN Gel outcomes.
